Asset
INSULIN GLARGINE
Eli Lilly and Company Common Stock
Revenue
| Period | Revenue |
|---|---|
| Q4 2024 | $853.8M |
| Q3 2024 | $161.6M |
| Q2 2024 | $180.8M |
| Q1 2024 | $157.6M |
| Q4 2023 | $913.5M |
| Q3 2023 | $179.6M |
| Q2 2023 | $154.2M |
| Q1 2023 | $209.3M |
| Q4 2022 | $962.1M |
| Q3 2022 | $193.0M |
Revenue as reported by this company. A combination product's amount appears on each of its constituent assets, so those figures are not additive. A fourth quarter is the reported full year less nine months, since no filing states one.
Clinical trials (32)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01374178 | phase1 | completed | 2011-06-01 | 2011-07-01 | Eli Lilly and Company | A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects |
| NCT02955953 | phase1 | completed | 2016-11-14 | 2017-01-04 | Eli Lilly and Company | A Study Comparing Two Formulations of Insulin Glargine in Healthy Participants |
| NCT01049412 | phase2 | completed | 2010-01-01 | 2010-12-01 | Eli Lilly and Company | A Study for Patients With Type 1 Diabetes |
| NCT00447213 | phase2_3 | completed | 2007-04-01 | 2008-05-01 | Eli Lilly and Company | A Study for Patients With Type 1 Diabetes Mellitus |
| NCT01421147 | phase3 | completed | 2011-08-01 | 2012-08-01 | Eli Lilly and Company | A Study in Adults With Type 1 Diabetes |
FDA applications (1)
| Application | Approved | Type | Applicant |
|---|---|---|---|
| BLA 205692 | 2015-12-16 | BLA | Eli Lilly and Company |
Marketed products (2)
- BASAGLAR
- Basaglar